^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Title:

Systemic Therapy for Melanoma: ASCO Guideline

Published date:
03/31/2020
Excerpt:
For patients with BRAF wild-type unresectable/metastatic cutaneous melanoma, the following treatment options should be offered (in no particular order): ipilimumab plus nivolumab followed by nivolumab OR nivolumab OR pembrolizumab...(Type: Evidence based, benefits outweigh harms; Evidence quality: High; Strength of recommendation: Strong).
DOI:
10.1200/JCO.20.00198